ResApp Health Limited (ASX: RAP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ResApp Health Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • ResApp Health Limited (ASX: RAP)
    Latest News

    a woman
    Share Gainers

    These ASX small cap shares are posting strong gains today

    The FBR Ltd (ASX:FBR) share price is one of three at the small end of the market posting strong gains…

    Read more »

    a woman
    Share Gainers

    These 3 small cap ASX shares are surging higher today

    The Biotron Limited (ASX:BIT) share price is one of three surging higher at the small end of the market on…

    Read more »

    a woman
    Share Gainers

    These small cap ASX shares have pushed higher on Wednesday

    The ResApp Health Ltd (ASX:RAP) share price is one of three pushing higher on Wednesday. Here's why...

    Read more »

    a woman
    Share Fallers

    Why ResApp Health Ltd (ASX:RAP) and Lovisa Holdings Ltd (ASX:LOV) are among 4 ASX shares sliding today

    Shares in Lovisa Holdings Ltd (ASX: LOV), ResApp Health Ltd (ASX: RAP) and BWX Limited (ASX: BWX) are in reverse…

    Read more »

    a woman
    Share Fallers

    Why these 4 ASX shares are sinking lower today

    The Resapp Health Ltd (ASX:RAP) share price is one of four sinking lower on the ASX on Tuesday. Here's why...

    Read more »

    a woman
    Share Fallers

    Why the ResApp Health Ltd (ASX:RAP) share price has been smashed today

    The ResApp Health Ltd (ASX:RAP) share price has been smashed today. It fell 59% in early trade following a disappointing…

    Read more »

    a woman
    Speculative

    Resapp Health Ltd (ASX:RAP) suspends trade on Smartcough results

    Resapp Health Ltd (ASX: RAP) has gone into voluntary trading suspension today

    Read more »

    a woman
    Share Market News

    Why these ASX shares are in trading halts today

    sApp Health Ltd (ASX:RAP) shares are one of three in trading halts today. Here's why...

    Read more »

    a woman
    Share Fallers

    ResApp Health Ltd (ASX:RAP) shares slide lower despite strong obstructive sleep apnoea study results

    The ResApp Health Ltd (ASX:RAP) share price has dropped lower despite the release of positive results from its obstructive sleep…

    Read more »

    a woman
    Share Market News

    Why these 3 ASX shares are in trading halts today

    ResApp Health Ltd (ASX:RAP) shares are one of three missing out on the market meltdown due to being in trading…

    Read more »

    a woman
    Share Fallers

    The ResApp Health Ltd (ASX:RAP) share price was smashed today

    ResApp Health Ltd (ASX:RAP) shares returned from a trading halt and were smashed today. Here's why...

    Read more »

    a woman
    Share Fallers

    Why these 4 ASX shares are tumbling lower today

    The TPG Telecom Ltd (ASX:TPM) share price is one of four tumbling lower today. Here's why...

    Read more »

    RAP ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Roger Aston Non-Executive ChairmanNon-Executive Director Jul 2015
    Dr Aston is a scientist and seasoned biotechnology entrepreneur. He has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include US Food and Drug Administration (FDA) and European Union (EU) product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston has also held Directorships/Chairmanships with Clinuvel Ltd, HalcyGen Ltd, and Ascent Pharma Ltd, was a member of the AusIndustry Biological Committee advising the Industry Research and Development Board.
    Dr Michael Stein Non-Executive Director Apr 2020
    Dr Stein is currently acting CEO of immuno-oncology company, Valo Therapeutics. Immediately prior to Valo, he was the founding CEO of OxStem Ltd, an award-winning biotechnology spinout from the University of Oxford. Dr Stein previously served as founding CEO for Doctor Care Anywhere, a UK-based telemedicine platform acquired by Synergix in 2015. In 2001, he cofounded the Map of Medicine with University College London and was founding CEO.
    Mr Brian Willoughby Leedman Executive Director Corporate Affairs May 2021
    Mr Leedman is a marketing and investor relations professional with over 15 years' experience in the biotechnology industry. Mr Leedman is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Ltd to form ResApp Health. Prior to ResApp, Mr Leedman co-founded Oncosil Medical Limited and Biolife Science (QLD) Limited (acquired by Imugene Limited).
    Mr Christopher Ntoumenopoulos Non-Executive Director Jan 2015
    Mr Ntoumenopoulos is the Managing Director of Twenty 1 Corporate. He has worked in financial markets for the past 15 years, focusing on Capital Raisings, Portfolio Management and Corporate Advisory. Mr Ntoumenopoulos has advised and funded numerous ASX companies from early stage venture capital, through to IPO.
    Dr Anthony (Tony) Keating Chief Executive OfficerManaging Director Jul 2015
    Dr Keating has over ten years' experience in commercialising technology. Dr Keating created the initial business strategy for ResApp and has led the commercialization of ResApp's technology to date. Previously, Dr Keating was Director, Commercial Engagement at UniQuest Pty Ltd, one of the global leaders in commercialisation of university technology. While at UniQuest, Dr Keating held roles as interim Chief Executive Officer and Non-Executive Director for a number of privately-held, venture-capital funded start-up companies.
    Ms Nicola (Nicki) Maxine Farley Company Secretary
    -
    Nicola (Nicki) Maxine Farley Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 90,509,172 10.53%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retail Client Drp> 46,498,352 5.41%
    J P Morgan Nominees Australia Pty Limited 22,398,291 2.61%
    Mr Frank Weng Thong Chew 18,453,000 2.15%
    HSBC Custody Nominees (Australia) Limited <GSCO Customers A/C> 17,974,966 2.09%
    BNP Paribas Noms Pty Ltd <DRP> 14,977,050 1.74%
    HSBC Custody Nominees (Australia) Limited GSCO ECA 12,567,531 1.46%
    Mr Yongsheng Peng & Mrs Yuezhen Xie 11,667,602 1.36%
    Mr Anthony James Keating 10,225,000 1.19%
    Citicorp Nominees Pty Limited 9,962,873 1.16%
    Equimetrixs Pty Ltd <The Newtonmore Superannuation fund A/C> 8,437,500 0.98%
    Narhex Life Sciences Developments Pty Ltd 7,997,005 0.93%
    CEM International (Asia) Pty Ltd 7,849,888 0.91%
    Norfolk Enchants Pty Ltd <Trojan Retirement Fund A/C> 7,510,228 0.87%
    Mr Trent Antony Goodrick 7,000,000 0.81%
    Queensland Forest Industries Pty Ltd 6,502,500 0.76%
    Mishtalem Pty Ltd 6,500,000 0.76%
    Super Dino Pty Ltd <Dino Super A/C> 5,430,779 0.63%
    HSBC Custody Nominees (Australia) Limited A/C 2 5,378,484 0.63%
    Paranji Super Fund Pty Ltd <Paranji Superfund A/C> 5,285,000 0.61%

    Profile

    since

    Note